About Bulkamid
Bulkamid is a Healthcare company based in London (United Kingdom) founded in 2003, and was acquired by Axonics in February 2021. It operates as a provider of the bulking agent for women urinary incontinence. Bulkamid offers products and services including Bulkamid Hydrogel. Its focus areas include Life Sciences, Women Health, Medical Devices and Therapy. Its legal entity is Axonics, Inc. Its competitors include Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and UroMems and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Bulkamid was founded in 2003 and is based in London, United Kingdom. Operations focus on the medical sector, specifically urological treatments. A bulking agent is supplied for addressing stress urinary incontinence and bladder leaks in women. In-home treatment options are available, along with developed medications targeted at urinary issues during activities such as coughing, walking, or exercising. Services are directed toward normalizing these conditions factually.
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bulkamid.com
- Social LinkedIn X
- Acquired by Axonics (Feb 2021)
- Legal Name Axonics, Inc.
Products & Services of Bulkamid
Bulkamid offers a comprehensive portfolio of products and services, including Bulkamid Hydrogel.
Injectable hydrogel for managing stress urinary incontinence symptoms.
Investors in Bulkamid
Bulkamid has secured backing from 1 investor. Prominent investors backing the company include Axonics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | axonics.com | Irvine, United States |
Investor details for Bulkamid
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Bulkamid
2 dated milestones of Bulkamid across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Bulkamid is founded.
- Exit Acquired by Axonics.
Competitors of Bulkamid
Bulkamid has 9 listed competitors in our database, 8 of them funded. They include Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and UroMems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| axonics.com | 2013 | Irvine, United States | $143.47M | 762 | Sacral neuromodulation devices are developed for urinary and bowel control. | |
| laborie.com | 1967 | Mississauga, Canada | – | 617 | Medical products for female lower urinary tract dysfunctions are provided. | |
| amber-tx.com | 2021 | London, United Kingdom | $100M | – | Bioelectrical therapies for peripheral nervous system disorders are developed. | |
| neuspera.com | 2014 | Santa Clara, United States | $123.59M | – | Miniaturized injectable neuromodulation devices are developed for chronic diseases. | |
| uromems.com | 2011 | Grenoble, France | $85.73M | – | Developer of active implantable devices for urological incontinence | |
| atlantictherapeutics.com | 2013 | Oranmore, Ireland | $70.62M | – | Non-invasive wearable devices for pelvic floor strengthening are developed. | |
| wearejude.com | 2021 | London, United Kingdom | $6.41M | 3 | Jude is focused on bladder health and protection products. | |
| myopowers.eu | 2004 | Besancon, France | $32.99M | – | An implantable device for the treatment of urinary incontinence stress | |
| leveemedical.com | 2021 | Durham, United States | $24.15M | – | Urological devices for post-prostatectomy incontinence are developed by Levee Medical. |
Detailed competitors of Bulkamid
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bulkamid
The website of Bulkamid (bulkamid.com) receives about 5.3K visits a month.
- Monthly visits5.3K
▼ 8.4% vs previous month
Top companies in Women's Health & Fertility
10 companies that operate in the same segment as Bulkamid (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 861 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bulkamid
Complete news archive for Bulkamid
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bulkamid
Bulkamid was founded in 2003.
Bulkamid is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Bulkamid was founded in 2003 and is based in London, United Kingdom. Operations focus on the medical sector, specifically urological treatments. A bulking agent is supplied for addressing stress urinary incontinence and bladder leaks in women. In-home treatment options are available, along with developed medications targeted at urinary issues during activities such as coughing, walking, or exercising. Services are directed toward normalizing these conditions factually.
Bulkamid's top competitors include Axonics, NeuSpera Medical and Laborie Medical.
Bulkamid offers Bulkamid Hydrogel.
Bulkamid has 1 investor. Key investors include Axonics.
Bulkamid operates through Axonics, Inc..
Yes. Bulkamid was acquired by Axonics in February 2021.